Ligand Pharmaceuticals Incorporated beat EPS estimates 81% of the time across 16 reported quarters (13 beats, 3 misses), averaging +34.7% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $1.34 | $2.22 | +65.7% | Beat | |
| Q1 FY26 | not reported | $-0.67 | not reported | not reported | Q1 FY26 call |
| Q4 FY25 | not reported | $2.12 | not reported | not reported | Q4 FY25 call |
| Q3 FY25 | not reported | $5.68 | not reported | not reported | |
| Q2 FY25 | $0.21 | $0.24 | +14.3% | Beat | Q2 FY25 call |
| Q1 FY25 | not reported | $-2.21 | not reported | not reported | |
| Q4 FY24 | not reported | $-1.64 | not reported | not reported | |
| Q3 FY24 | not reported | $-0.39 | not reported | not reported | |
| Q2 FY24 | $0.82 | $0.92 | +12.2% | Beat | |
| Q1 FY24 | $0.82 | $0.80 | -2.4% | Miss | |
| Q4 FY23 | not reported | $0.79 | not reported | not reported | |
| Q3 FY23 | $0.36 | $0.71 | +97.2% | Beat |
Back to LGND overview · LGND holders · LGND KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.